1Siragy,H.M.AT1 and AT2 receptor in the kidney:role in health and disease.Semin Nephrol 2004 ;24,93-100.
2Lansang,M.C.et al.Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus,Kidney Int 2001; 59,1432-1438.
3Nguyen,G.,Delarue,F.,Berrou,J.,Rondeau,E.& Sraer,J.D.Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen.Kideney Int 1996;50,1897-1903.
4Huang,X.R.,Chen,W.Y.,Truong,L.D.& Lan,H.Y.Chymase is upregulated in diabetic nephropathy:implications for an alternative pathway of angiotensin Ⅱ -mediated diabetic renal and vascular disease.J Am Soc Nephrol 2003;14,1738-1747.
5Hollenberg,N.K.,Fisher,N.D.& Price,D.A.Pathways for angiotensin Ⅱ generation in intact human tissue:evidence form comparative pharmacological interruption of the renin system.Hypertension 1998;32,387-392.
6Tipnis,S.R.et al.A human homolog of angiotensin-converting enzyme.Cloning and functional expression as a captopril-insensitive carboxypeptidase.J Biol Chem 2000;275,33238-33243.
7Donoghue,M.et al.A novel angiotensin-converting enzyme-related carboxypeptidase(ACE2) converts angiotensin Ⅰ to angiotensin 1-9.Circ Res 2000; 87,E1-9.
8Crackower,M.A.et al.Angiotensin-converting enzyme 2 is an essential regulator of heart function.Nature 2002 ;417,822-828.
9Tikellis,C.et al.Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy.Hypertension 2003 ;41,392 -397.
10Wolf,G.New insights into the pathophysiology of diabetic nephropathy:from haemodynamics to molecular pathology.Eur J Clin Invest 2004;34,785-796.
同被引文献2
1The TIMAD.Study Group:Ticlopidine treatment redecus the progression of nonproliferative[J].Diabetes retinopathy,Arch.Odphthalmol,1990,108:1577.
